Shares of Relief Therapeutics’ (SIX: RLF) erupted over 90% after its RLF-100 COVID-19 treatment showed an early potential in the second testing phase.
RLF-100, patented by Relief Therapeutics’ and further developed by NeuroRx for the market of the United States, is designed to treat critically ill COVID-19 patients.
“We are conducting placebo-controlled trials to see whether the observations made in the case-control and open-label studies will be confirmed for less ill patients with COVID-19-related respiratory failure,” NeuroRx CEO Jonathan Javitt said.
Interested in investing after today’s move?
XTB gives investors access to thousands of UK and international stocks,
including fractional shares from just £1.
Explore stocks with XTB →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Want to invest in the stocks making the news?
Go from following the market to investing in it, with access to thousands
of stocks across major UK and international markets.
See available stocks →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Own the stocks you’re reading about
Invest in real shares across the UK, US and other major global markets
through XTB, all from one investment account.
Explore XTB shares →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
You don’t need to buy a whole share
Fractional shares let you invest from just £1, giving you more control
over how much you put into individual companies.
Explore fractional shares →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Want to see how XTB works first?
Explore the platform with an XTB demo account before deciding whether
you want to invest with real money.
Try the XTB demo →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
“No other antiviral agent has demonstrated rapid recovery from viral infection and demonstrated laboratory inhibition of viral replication”.
According to the joint statement, around 70 patients are participating in the second testing phase. Two firms said that over 15 patients showed signs of progress after receiving RLF-100 for three days.
The drug was granted the fast-track designation in the United States by the U.S. Food and Drug Administration (FDA).
Relief and NeuroRx said that an independent data monitoring committee will analyze the data from tests later this month.
Relief Therapeutics’ share price skyrocketed 90% to 0.064, trading close to the record highs set in March this year.
